Gadoxetic Acid-Enhanced MRI-Based Radiomics Signature: A Potential Imaging Biomarker for Identifying Cytokeratin 19-Positive Hepatocellular Carcinoma

Table 1

Baseline characteristics of the study population.

	All ()	CK19 (-) ()	CK19 (+) ()	value
Gender				0.68
Male	100 (90.9%)	83 (91.2%)	17 (89.5%)
Female	10 (9.09%)	8 (8.79%)	2 (10.5%)
Age (years)				0.36
<60	74 (67.3%)	59 (64.8%)	15 (78.9%)
≥60	36 (32.7%)	32 (35.2%)	4 (21.1%)
HBV infection				0.47
No	16 (14.5%)	12 (13.2%)	4 (21.1%)
Yes	94 (85.5%)	79 (86.8%)	15 (78.9%)
Cirrhosis status				0.60
No	61 (55.5%)	52 (57.1%)	9 (47.4%)
Yes	49 (44.5%)	39 (42.9%)	10 (52.6%)
ALBI grade				0.52
Grade1	42 (38.2%)	33 (36.3%)	9 (47.4%)
Grade2	68 (61.8%)	58 (63.7%)	10 (52.6%)
MELD score				0.68
<9	100 (90.9%)	83 (91.2%)	17 (89.5%)
≥9	10 (9.09%)	8 (8.79%)	2 (10.5%)
Tumor size (cm)				0.50
<5 cm	57 (51.8%)	49 (53.8%)	8 (42.1%)
≥5 cm	53 (48.2%)	42 (46.2%)	11 (57.9%)
AST (U/L)				1.000
<40	81 (73.6%)	67 (73.6%)	14 (73.7%)
≥40	29 (26.4%)	24 (26.4%)	5 (26.3%)
ALT (U/L)				0.59
<40	78 (70.9%)	66 (72.5%)	12 (63.2%)
≥40	32 (29.1%)	25 (27.5%)	7 (36.8%)
PT (second)				0.33
<12.1	20 (18.2%)	15 (16.5%)	5 (26.3%)
≥12.1	90 (81.8%)	76 (83.5%)	14 (73.7%)
Platelet (×10^9/L)				0.36
<125	21 (19.1%)	16 (17.6%)	5 (26.3%)
≥125	89 (80.9%)	75 (82.4%)	14 (73.7%)
Serum AFP (ng/mL)				0.002
<400	76 (69.1%)	69 (75.8%)	7 (36.8%)
≥400	34 (30.9%)	22 (24.2%)	12 (63.2%)
Serum CA 19-9 (U/mL)				0.04
<34	92 (83.6%)	73 (80.2%)	19 (100%)
≥34	18 (16.4%)	18 (19.8%)	0 (0.00%)
Serum CEA (ng/mL)				0.69
<5	99 (90.0%)	81 (89.0%)	18 (94.7%)
≥5	11 (10.0%)	10 (11.0%)	1 (5.26%)

. AFP: alpha fetoprotein; ALBI: albumin-bilirubin grade; ALT: alanine aminotransferase; AST: aspartate aminotransferase; CA 19-9: carbohydrate antigen 19-9; CEA: carcinoembryonic antigen; CK19: cytokeratin 19; HBV: hepatitis B virus; MELD score: Model for End-Stage Liver Disease score; OR: odds ratio; PT: prothrombin time.